Sedef, A. M. Et Al. 2015. Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?. MEDICAL ONCOLOGY , vol.32, no.2 .

Sedef, A. M., Kose, F., Sumbul, A. T., Dogan, O., BESEN, A. A., Tatli, A. M., ... Mertsoylu, H.(2015). Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?. MEDICAL ONCOLOGY , vol.32, no.2.

Sedef, Ali Et Al. "Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?," MEDICAL ONCOLOGY , vol.32, no.2, 2015

Sedef, Ali M. Et Al. "Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?." MEDICAL ONCOLOGY , vol.32, no.2, 2015

Sedef, A. M. Et Al. (2015) . "Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?." MEDICAL ONCOLOGY , vol.32, no.2.

@article{article, author={Ali Murat Sedef Et Al. }, title={Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?}, journal={MEDICAL ONCOLOGY}, year=2015}